Entera Bio Ltd. Gross Margin

Gross Margin of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.

Highlights and Quick Summary

  • Gross Margin for the quarter ending June 29, 2020 was 40.38% (a Infinity% increase compared to previous quarter)
  • Year-over-year quarterly Gross Margin increased by 21.15%
  • Annual Gross Margin for 2019 was 11.02% (a -88.98% decrease from previous year)
  • Twelve month Gross Margin ending June 29, 2020 was 18.36% (a Infinity% increase compared to previous quarter)
Trailing Gross Margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19
18.36% 0.0% 71.47%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Entera Bio Ltd.

Most recent Gross Marginof ENTX including historical data for past 10 years.

Interactive Chart of Gross Margin of Entera Bio Ltd.

Entera Bio Ltd. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 40.38% 0.0%
2019 -5.88% 33.33% 16.22% 11.02%
2018 100.0% 100.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.